Prot #TAK-500-1001: An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a

Project: Research project

Project Details

StatusActive
Effective start/end date4/2/24 → 4/2/27

Funding

  • PPD Investigator Services, LLC (Prot #TAK-500-1001 // Prot #TAK-500-1001)
  • Takeda Development Center Americas, Inc. (Prot #TAK-500-1001 // Prot #TAK-500-1001)